Physician profile
Lawrence A Pardee
NPI 1417963166
$159,258.28
in general payments reported to CMS, 2019-2025
52 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $17K · 2021: $41K · 2022: $30K · 2023: $19K · 2024: $19K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $7,996 · Consulting Fee: $1,900 · Education: $253 · Travel and Lodging: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,285.00 |
| Food and Beverage | $7,995.57 |
| Consulting Fee | $1,900.00 |
| Education | $252.70 |
| Travel and Lodging | $190.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $71,015.12 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $21,930.43 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biohaven Pharmaceuticals, INC. | $16,029.71 | 2021 | |
| Allergan, INC. | $13,058.73 | 2019-2022 | |
| Genzyme Corporation | $10,500.35 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $10,020.03 | 2022 | |
| Lundbeck LLC | $3,357.49 | 2019-2025 | Vyepti |
| Pfizer INC. | $2,812.95 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $2,708.88 | 2019-2024 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $1,034.41 | 2019-2021 | |
| Amgen INC. | $803.09 | 2019-2025 | Aimovig, Uplizna |
| Lilly USA, LLC | $498.06 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $472.51 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Jazz Pharmaceuticals INC. | $459.69 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $430.28 | 2019-2025 | Nuplazid |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Pardee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.